TABLE 3

Analysis of the serum inflammatory marker data: ratio of AZD5069 80 mg twice daily to placebo in the pharmacodynamics analysis set

BaselineEnd of treatmentANCOVAp-value
Ratio of end of treatment to baselineRatio of AZD5069 80 mg twice daily to placebo
Subjects nGeo meanCV %Subjects nGeo meanCV %Subjects nRatio (90% CI)Subjects nRatio (90% CI)
CRP mg·L−1
  Placebo246.3185.6245.1228.2240.8 (0·6–1.1)
  AZD5069245.8130.4247.7120.1241.3 (0.9–1.8)481.5 (1.0–2.4)0.112
IL-8 pg·mL−1
  Placebo2416.645.52415.358.2241.0 (0.8–1.2)
  AZD50692412.936.42480.283.9245.9 (4.7–7.3)486.1 (4.4–8.4)<0.001
IL-6 pg·mL−1
  Placebo243.4104.8243.297.5241.0 (0.8–1.2)
  AZD5069242.3109.0243.288.3241.1 (1.0–1.3)481.2 (0.9–1.5)0.281
IL-1β pg·mL−1
  Placebo240.764.5240.674.2240.9 (0.8–1.1)
  AZD5069240.688.2240.989.2241.5 (1.3–1.7)481.6 (1.3–1.9)0.001
GRO-α pg·mL−1
  Placebo24146.443.824146.148.6241.0 (0.8–1.2)
  AZD506916156.937.516846.891.8165.5 (4.4–6.7)405.5 (4.2–7.2)<0.001
TNF-α pg·mL−1
  Placebo249.426.9248.917.9241.0 (0.9–1.0)
  AZD5069248.734.7249.023.5241.0 (1.0–1.1)481.1 (1.0–1.1)0.241
SAA ng·mL−1
  Placebo249924.2243.7248594.3300.0240.9 (0.6–1.3)
  AZD5069248865.5209.82410 781.3230.2241.2 (0.8–1.7)481.3 (0.8–2.3)0.367
  • Geo mean: geometric mean; CV: coefficient of variation; CRP: C-reactive protein; IL: interleukin; GRO: growth-regulated oncogene; TNF: tumour necrosis factor; SAA: serum amyloid-A.